Back to Journals » OncoTargets and Therapy » Volume 10

Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant

Authors Zhao Z, Song ZJ, Wang XW, Sun HF, Yang XM, Yuan Y, Yu P

Received 6 March 2017

Accepted for publication 13 June 2017

Published 21 August 2017 Volume 2017:10 Pages 4129—4133

DOI https://doi.org/10.2147/OTT.S136297

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Dr Tohru Yamada

Video abstract presented by Zheng Zhao

Views: 37

Zheng Zhao,1 Zhangjun Song,2 Xuwei Wang,3 Haifeng Sun,1 Xiaomin Yang,2 Yong Yuan,4 Pan Yu3

1Third Department of Medical Oncology, Shannxi Provincial Cancer Hospital, 2Breast Surgery Center, Shannxi Provincial Cancer Hospital, Xi’an, 3Marketing Department, Novogene Bioinformatics Institute, Beijing, 4Pathology Department, Shannxi Provincial Cancer Hospital, Xi’an, People’s Republic of China

Abstract: ROS1 fusion is a common genetic alteration in non-small-cell lung cancer. Crizotinib, an anaplastic lymphoma kinase inhibitor, shows efficacy in the treatment of lung cancer cases with ROS1 translocation. We report the response to crizotinib of a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant, which was different from the two common SLC34A2-ROS1 fusion types reported in the literature. After crizotinib administration, overall recovery was good in this patient; the primary lesion was successfully treated, the lymph node metastases had disappeared, and the metabolism was normal.

Keywords: SLC34A2-ROS1 fusion, crizotinib, lung adenocarcinoma, next-generation sequencing

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]